GVR Report cover Fabry Disease Treatment Market Size, Share & Trends Report

Fabry Disease Treatment Market Size, Share & Trends Analysis Report By Treatment (Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT), Chaperone Treatment), By Region, And Segment Forecasts, 2019 - 2025

  • Report ID: GVR-2-68038-747-6
  • Number of Pages: 75
  • Format: Electronic (PDF)

Industry Insights

The global Fabry disease treatment market size was valued at USD 1.57 billion in 2017. It is anticipated to progress at a CAGR of 9.6% over the forecast period. Expanding base of patients suffering from Fabry disease coupled with increased adoption of novel therapies such as chaperone treatment has helped the market gain momentum. Besides this, extensive R&D activities and potential approval of promising pipeline products including substrate reduction therapies and enzyme replacement therapies are projected to escalate the growth of the over the forecast period.

Fabry disease is a rare X-linked lysosomal storage disorder with a deficiency of alpha-galactosidase enzyme resulting in progressive organ dysfunction. This disease is caused by an abnormal buildup of a specific fatty matter called globotriaosylceramide in multiple tissues of the body including eyes, skin, kidney, gastrointestinal system, brain, heart, and central nervous system.

U.S. Fabry Disease Treatment market

Patients suffering from Fabry disease commonly progress to a stage of severe pain of extremities, compromised kidney function often progressing to full kidney failure, early heart disorder, stroke, and disabling gastrointestinal symptoms. Because of the lack of a curative solution for Fabry disease, treatment options generally aim at the management of complications associated with disease progression and providing symptomatic relief.

Current treatments include enzyme replacement therapy (ERT), chaperone treatment, and substrate reduction therapy (SRT). Prior to enzyme replacement therapy, there were no effective treatments for Fabry and the average life expectancy of a Fabry patient was 40 to 50 years of age.

Many patients remain undiagnosed due to the disease’s late-onset and moderate symptoms. Although accurate data on prevalence is not available, according to Sanofi, around 3,000 patients suffer from Fabry disease in the U.S., and a similar number of patients are affected in other countries. Fabry patients on average live longer in comparison to patients with other lysosomal storage disorders.

Treatment Insights

On the basis of treatment type, the global Fabry disease treatment market has been categorized into enzyme replacement therapy (ERT), chaperone treatment, substrate reduction therapy (SRT), and others. The Standard of care for disease management is enzyme replacement therapy. Although, both the ERTs, Sanofi’s Fabrazyme and Shire’s Replagal, have been approved in Europe, only Fabrazyme has been approved in the U.S. The focus of current clinical trials is to improve safety and efficacy profile of ERTs and introduction of novel oral therapies that can eliminate the need for intravenous infusions. Recently Amicus Therapeutics’ Galafold has been approved as the first oral chaperone therapy for the treatment of adult patients in the U.S., Canada, EU, Japan, Australia, Israel, and South Korea.

North America Fabry Disease Treatment market

The enzyme replacement therapy segment held the largest market share in 2017. It is poised to retain its position through 2025. Strong sales of Fabrazyme and Replagal and potential approval of promising pipeline candidates are supporting the dominance of the segment. However, the launch of new efficacious therapeutic options such as gene therapies is much needed for a noteworthy increase in patient benefits.

Regional Insights

North America was the most prominent regional market in 2017, followed by Europe. Higher adoption of novel therapies, better healthcare facilities, and favorable reimbursement policies are playing a vital role in the growth of the market in the region.

Coverage of expensive medications such as Fabrazyme by health insurance programs and favorable governmental healthcare policies are also prompting drug companies to increase R&D investments in the field of rare diseases.

Asia Pacific presents immense growth opportunities for pharmaceutical companies due to increasing healthcare expenditure and improving infrastructure. The region is likely to experience the fastest growth during the forecast period, followed by Latin America, primarily due to large populations in emerging countries.

Fabry Disease Treatment Market Share Insights

Sanofi is at the forefront of the global arena due to strong sales of their marketed drug Fabrazyme for the treatment of Fabry disease. Sanofi is closely followed by Shire, whose product, Replagal, has not been approved by the FDA. However, Sanofi and Shire are expected to face stiff competition from biosimilar launches during the forecast period. Furthermore, Amicus Therapeutics is emerging as a global player in rare disease space with the launch of Galafold, the first oral treatment for Fabry disease. Idorsia and Avrobio are also estimated to command a significant share due to the growing popularity of substrate reduction therapies and gene therapies in the market with potential launches of their pipeline products lucerastat and AVR-RD-01, respectively.

Some of the key players operating in the market are Sanofi S.A.; Shire Plc.; Amicus Therapeutics Inc.; ISU Abxis Co Ltd.; JCR Pharmaceuticals Co Ltd.; Protalix Biotherapeutics Inc.; Idorsia Pharmaceuticals Ltd.; Avrobio Inc.; Greenovation Biotech GmbH; Moderna Therapeutics Inc.; and Green Cross Pharma Pte Ltd. The players are engaged in strategic planning, development of novel therapies, and deals to accomplish widespread growth and obtain the leading position in the market.

Report Scope



Base year for estimation


Actual estimates/Historical data


Forecast period

2018 - 2025

Market representation

Revenue in USD Million & CAGR from 2018 to 2025

Regional scope

North America, Europe, Asia Pacific, Latin America, MEA

Country scope

U.S., Canada, U.K., Germany, Japan, China, India, Brazil, Mexico, South Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors and trends

15% free customization scope (equivalent to 5 analyst working days)

If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of industry trends in each of the sub segments from 2016 to 2025. For the purpose of this study, Grand View Research has segmented the global Fabry disease treatment market report on the basis of treatment and region:

  • Treatment Outlook (Revenue, USD Million, 2016 - 2025)

    • Enzyme Replacement Therapy (ERT)

    • Chaperone Treatment

    • Substrate Reduction Therapy (SRT)

    • Others

  • Regional Outlook (Revenue, USD Million, 2016 - 2025)

    • North America

      • The U.S.

      • Canada

    • Europe

      • Germany

      • U.K.

    • Asia Pacific

      • Japan

      • China

      • India

    • Latin America

      • Brazil

      • Mexico

    • MEA

      • South Africa

gvr icn


gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member


ISO Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.

great place to work icon